Monte Rosa's MRT-2359 Shows Promising Results in AR-Mutant Prostate Cancer
Event summary
- Monte Rosa Therapeutics presented updated Phase 1/2 data for MRT-2359 + enzalutamide in mCRPC patients at ASCO GU 2026, showing 100% PSA response rate in AR-mutant subset (5/5 patients).
- Overall RECIST disease control rate was 67% across 15 evaluable patients, with 10 showing tumor size reductions.
- Combination therapy was well-tolerated with primarily Grade 1-2 adverse events; no treatment discontinuations due to AEs.
- Company plans to initiate a signal-confirming Phase 2 study in Q3 2026 targeting AR-mutant mCRPC patients.
The big picture
Monte Rosa's data suggests MRT-2359 could address a critical unmet need in AR-mutant mCRPC, a population with limited treatment options. The molecular glue degrader approach represents a novel therapeutic strategy in oncology, potentially offering advantages over traditional small-molecule inhibitors. Success in this indication could validate the broader platform and attract partnership interest.
What we're watching
- Clinical Validation
- Whether the Phase 2 study can confirm and expand these results in AR-mutant mCRPC patients, positioning MRT-2359 for potential registrational trials.
- Competitive Positioning
- How Monte Rosa differentiates MRT-2359 in the crowded mCRPC treatment landscape, particularly against established AR inhibitors like enzalutamide and emerging therapies like Pluvicto®.
- Development Timeline
- The pace at which Monte Rosa can advance MRT-2359 through subsequent clinical phases, given the positive early data and planned Phase 2 initiation in Q3 2026.
Related topics